TidalSense provides a point‑of‑care platform for diagnosing and monitoring chronic respiratory diseases such as COPD and asthma. Its N‑Tidal® system combines a patented sensor, a 4G‑connected handset, and AI‑driven analytics to deliver rapid, accurate diagnoses and continuous digital biomarkers for remote patient monitoring, enabling early intervention and reducing hospitalisations. The service is offered as a fully managed solution for clinicians and healthcare systems.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCBDFGFounders
Product
Problem
Chronic obstructive pulmonary disease (COPD) and asthma are under‑diagnosed and often identified late, leading to costly exacerbations, hospitalisations, and reduced patient outcomes. Current diagnostic tools such as spirometry are complex, require specialist training, and are not widely accessible in primary‑care or community settings.
Solution
TidalSense offers the N‑Tidal platform, a CE‑marked point‑of‑care system that combines a patented CO₂ sensor with AI‑driven analysis to diagnose COPD and monitor obstructive airway conditions in minutes. The handheld device captures high‑resolution breath waveforms during 75 seconds of relaxed tidal breathing, then automatically uploads data via built‑in 4G to a secure cloud where proprietary algorithms generate digital biomarkers and a diagnostic report. Results—including severity staging—are delivered within five minutes through an online dashboard or downloadable PDF, eliminating the need for specialist interpretation. A complementary remote‑monitoring solution, N‑Tidal Capture, continuously tracks these biomarkers for patients at home, providing clinicians with longitudinal data to guide treatment adjustments. The service is delivered as a fully managed, pay‑per‑test model, removing upfront hardware costs and simplifying workflow integration.
Target Audience
Primary customers are primary‑care clinics, respiratory specialists, and healthcare systems seeking rapid, accurate COPD diagnosis and ongoing monitoring for patients with obstructive airway diseases.
Features
- Patented CO₂ sensor that records high‑resolution breath waveforms from 75 seconds of relaxed breathing
- Real‑time geometric analysis of CO₂ waveforms to quantify lung function without forced maneuvers
- Regulated Class 2a medical device combined with AI algorithms achieving ~90 % sensitivity and 88 % specificity for COPD detection
- Automatic 4G data transmission and cloud‑based processing into digital biomarkers and diagnostic reports
- Point‑of‑care diagnostic service (N‑Tidal Diagnose) with results available in ≤5 minutes via web dashboard or PDF
- Remote patient monitoring (N‑Tidal Capture) delivering longitudinal biomarker trends to clinicians through a secure dashboard
- Portable, cordless handset with long battery life, no Wi‑Fi pairing, and reusable consumables for easy disinfection